Compare Mesoblast Limited (MESO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Meta Platforms Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Meta Platforms Inc trades at $722.64 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 1016.6× Mesoblast Limited's market cap, and Meta Platforms Inc pays a 0.29% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Meta Platforms Inc for 127 Days on average.
| MESO | META | |
|---|---|---|
Market Cap | $1.81B | $1.84T |
Volume | 240,620 | 12,743,601 |
Sector | Health | Media |
52-Week High | $20.96 | $777.59 |
52-Week Low | $13.19 | $525.72 |
Typical Hold Time | 14 Days | 127 Days |
Enterprise Value | $1.89B | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Meta Platforms (META) trades at $720.89, down 2.43% on the day, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.8% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B partnership with CoreWeave highlight growth initiatives. Analyst consensus remains strongly bullish with 80% buy ratings and a $781 price target.
Meta presents a compelling investment case with strong profitability metrics and AI-driven growth potential, though faces regulatory risks from ongoing litigation and significant capital expenditure requirements. The stock's current valuation at 27x P/E appears reasonable given growth prospects, but investors should monitor execution on AI monetization and legal developments that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
